Inhalation Sciences wins new IRS order worth 100,000 Euro (1.14 MSEK) from prominent European pharma company
Inhalation Sciences AB (ISAB) has received a new order worth 100 kEuro (1.14 MSEK) for an Inhalation Research Services (IRS) project from a major European company with a leading pipeline in inhaled therapies, that is a regular client of both ISAB’s products and services. The project will use ISAB’s XposeALI in vitro exposure module.
ISAB’s XposeALI in vitro cell exposure module is connected to the company’s multi-modular aerosol generating platform PreciseInhale. The set-up delivers a precise and even dispersion of test aerosol particles directly onto the cell surface, hence the exposure is called “Air-Liquid Interface”, simulating what occurs on the lung lining when the drug is inhaled.
Reducing test substance costs
The cost of test substances and animal testing is a substantial and growing expense in the development of inhaled therapies. The XposeALI in vitro method significantly reduces the amount of test materials required, as PreciseInhale allows customizable doses of aerosol using minimal amounts of test substance. A full PK study using PreciseInhale can require as little as 100 milligrams of test substance compared to 100g using conventional methods.
Minimizing animal testing
In vitro testing is growing in importance also in the frame of regulatory guidelines, possibly reducing the future need for animal testing. This not only cuts costs but also aligns with 3R guidelines, a guiding framework on the ethical use of animals recognized by much of the industry and its funding bodies.
Leading the way in in vitro testing
ISAB is increasingly gaining a reputation as a leading innovator and provider of in vitro research services, offering permeability and dissolution studies for inhaled drug development through instruments like XposeALI and its in vitro dissolution testing module DissolvIt.
CEO Manoush Masarrat: “Once again we’re witnessing the growing demand for advanced in vitro testing systems like XposeALI, as the powerful benefits are increasingly understood and recognized. We extend a warm welcome to our returning client”.
Discover ISAB’s in vitro testing modules
- Read ISAB’s publications on XposeALI here.
- Discover XposeALI’s capabilities here.
- Read ISAB’s publications on DissolvIthere.
- Discover DissolvIt’s in vitro capabilities here.
- Explore Inhalation Research Services here.
For more information about Inhalation Sciences, please contact: Manoush Masarrat, CEO E-mail: Manoush.email@example.com Mobile: +46 (0)73 628 9153Press release in PDF format